Please login to the form below

Not currently logged in


This page shows the latest 177Lu-PSMA-617 news and features for those working in and with pharma, biotech and healthcare.

Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO

Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO

mCRPC patients treated with Lu-PSMA-617 plus best standard of care achieved a 38% reduction in the risk of death. ... This] data from the first phase 3 study of a radioligand therapy in this advanced prostate cancer setting confirm[s] the potential of

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Endocyte’s lead clinical product is 177Lu‐PSMA‐617, which uses its proprietary drug conjugation technology to deliver Lutetium‐177 directly to tumours. ... the TRiM platform, for chronic HBV infection. Licence. $3.7B. Endocyte /. Novartis.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....